Retension Pharmaceuticals, Inc. Common Stock (RTSN)

Nasdaq · Healthcare · Biotechnology

$10.53−12.25%as of Oct 10, 2026, 1:07 AM ET

Market cap: $83.0M
52-week range: $9.66 – $11.60

About Retension Pharmaceuticals, Inc. Common Stock

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.

Headquarters: Falls Church, United States · retensionpharmaceuticals.com